RSS Feeds
Amoxapine Overdose: Report of Two Patients with Severe Neurologic Damage
- MARK J. GOLDBERG, M.D.; and
- REYNOLD SPECTOR, M.D.
Excerpt
Amoxapine (Asendin, Lederle Laboratories, Pearl River, New York), a tricyclic dibenzoxazepine antidepressant, has been recently marketed in the United States. Development of new tricyclic antidepressants has continued in part because of the severe cardiovascular and central nervous system toxicity associated with overdoses of previous tricyclic antidepressants (1). We report two cases in which overdoses of amoxapine resulted in irreversible central nervous system damage.
A 24-year-old healthy woman took approximately 4 g of amoxapine. She then slept for 4 hours before she was taken to the University of Iowa Hospitals on 12 May 1981. Initially, she was alert; she complained of
This 100-word excerpt has been provided in the absence of an abstract.
Article and Author Information
-
Supported in part by grants from the Pharmaceutical Manufacturer's Association Foundation and the Burroughs Wellcome Fund.
-
▸Requests for reprints should be addressed to Mark J. Goldberg, M.D.; University of Iowa Hospitals, Department of Medicine; Iowa City, IA 52242.
